Agenus News - AGEN

Company Name	Stock Ticker Symbol	Market	Type
Agenus Inc	AGEN	NASDAQ	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	0.61	12.27%	5.58	11:37:09

Open Price	Low Price	High Price	Close Price	Prev Close
4.96	4.9001	5.87		4.97

more quote information »

Recent News

Date	Time	Source	Heading
4/12/2024	07:30	BW	Agenus Announces Updated Phase 1 Data and Progress on..
4/05/2024	16:30	BW	Agenus Announces Reverse Stock Split of Common Stock
3/14/2024	07:30	BW	Agenus Reports Fourth Quarter and Full Year 2023 Results
3/06/2024	07:30	BW	Agenus Announces Preclinical Data on BMS-986442 (AGEN1777)..
3/05/2024	16:30	BW	Agenus Reports Inducement Grants Under Nasdaq Listing Rule..
2/29/2024	16:50	EDGAR2	Form DEFA14A - Additional definitive proxy soliciting..
2/29/2024	07:30	BW	Agenus to Provide Corporate Update and Fourth Quarter & Full..
2/26/2024	16:24	EDGAR2	Form DEF 14A - Other definitive proxy statements
2/26/2024	07:30	BW	Agenus to Participate in Leerink Partners Global Biopharma..
2/15/2024	08:02	EDGAR2	Form PRE 14A - Other preliminary proxy statements
2/15/2024	08:00	EDGAR2	Form 8-K - Current report
2/15/2024	07:02	PRNUS	Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to..
2/14/2024	08:33	EDGAR2	Form SC 13G/A - Statement of acquisition of beneficial..
2/12/2024	07:00	EDGAR2	Form 5 - Annual statement of changes in beneficial ownership..
2/09/2024	17:11	EDGAR2	Form SC 13G/A - Statement of acquisition of beneficial..
1/31/2024	08:00	EDGAR2	Form 8-K - Current report
1/31/2024	07:30	BW	Agenus to Participate in Oppenheimer 34th Annual Healthcare..
1/22/2024	09:59	BW	Botensilimab/Balstilimab Breakthrough Data Presented at..
1/22/2024	07:30	BW	Botensilimab/Balstilimab Breakthrough Data Presented at..
1/05/2024	16:30	BW	Agenus Reports Inducement Grants Under Nasdaq Listing Rule..
1/04/2024	07:30	BW	Agenus to Participate in B. Riley Healthcare Conference
1/04/2024	06:06	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
1/04/2024	06:05	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
1/04/2024	06:05	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/20/2023	07:30	BW	Botensilimab/Balstilimab Data in Neoadjuvant Colorectal..
12/11/2023	07:30	BW	Agenus to Receive $25 Million Milestone Payment from Bristol..
12/08/2023	16:15	EDGAR2	Form 8-K - Current report
11/17/2023	16:22	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
11/09/2023	16:11	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/07/2023	06:30	EDGAR2	Form 8-K - Current report
11/07/2023	06:30	BW	Agenus Reports Third Quarter 2023 Results
10/26/2023	09:05	BW	Agenus to Provide Third Quarter 2023 Financial Report and..
10/22/2023	12:00	BW	Agenus Unveils New and Updated Botensilimab Data in..
10/21/2023	04:15	BW	ESMO 2023: Agenus’ Botensilimab/Balstilimab Combination..
10/16/2023	17:49	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/10/2023	07:30	BW	Agenus Completes Enrollment in Randomized Phase 2 Clinical..
10/06/2023	16:26	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/05/2023	07:30	BW	Agenus To Host BOT/BAL Program Update at ESMO 2023
10/04/2023	17:12	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/04/2023	17:11	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/04/2023	17:01	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
9/01/2023	16:30	BW	Agenus Reports Inducement Grants Under Nasdaq Listing Rule..
8/31/2023	17:53	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
8/28/2023	17:15	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
8/28/2023	07:30	BW	Agenus to Participate in September Investor Conferences
8/23/2023	08:00	EDGAR2	Form 8-K - Current report
8/23/2023	08:00	BW	Agenus Prioritizes Resources to Accelerate Registration and..
8/09/2023	08:30	BW	SaponiQx Announces Breakthrough in Scaling Up of STIMULON™..
8/08/2023	16:04	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/08/2023	07:30	EDGAR2	Form 8-K - Current report